Global Blood Therapeutics, Inc.

NasdaqGS:GBT Stock Report

Market Cap: US$4.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Global Blood Therapeutics Management

Management criteria checks 4/4

Global Blood Therapeutics' CEO is Ted Love, appointed in Jun 2014, has a tenure of 8.33 years. total yearly compensation is $8.19M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 1.37% of the company’s shares, worth $63.19M. The average tenure of the management team and the board of directors is 6.5 years and 5.8 years respectively.

Key information

Ted Love

Chief executive officer

US$8.2m

Total compensation

CEO salary percentage8.7%
CEO tenure8.3yrs
CEO ownership1.4%
Management average tenure6.5yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Global Blood Therapeutics expects to complete Pfizer deal in early October

Sep 30

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Sep 16

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Aug 24

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Aug 08

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Jul 14

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Jun 29

Global Blood Therapeutics: Powerhouse Of The Future

Jun 21

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Jun 07
Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Global Blood Therapeutics: Hitting A Growth Inflection

Apr 12

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Mar 12

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Feb 24
Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics: Revisiting A Stellar Grower

Dec 25

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Nov 30

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Nov 03
Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Oct 24

Global Blood Therapeutics: Attempting To Classify The Investment

Aug 07

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jul 08
Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Global Blood Therapeutics announces employment inducement grants

Jun 04

Global Blood Therapeutics: Increasing Specialization In SCD

May 09

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Mar 18
Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Feb 20
Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Jan 25
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

Dec 29
Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

CEO Compensation Analysis

How has Ted Love's remuneration changed compared to Global Blood Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$322m

Mar 31 2022n/an/a

-US$310m

Dec 31 2021US$8mUS$716k

-US$303m

Sep 30 2021n/an/a

-US$277m

Jun 30 2021n/an/a

-US$266m

Mar 31 2021n/an/a

-US$249m

Dec 31 2020US$18mUS$661k

-US$248m

Sep 30 2020n/an/a

-US$282m

Jun 30 2020n/an/a

-US$286m

Mar 31 2020n/an/a

-US$291m

Dec 31 2019US$10mUS$597k

-US$267m

Sep 30 2019n/an/a

-US$220m

Jun 30 2019n/an/a

-US$199m

Mar 31 2019n/an/a

-US$182m

Dec 31 2018US$10mUS$569k

-US$174m

Sep 30 2018n/an/a

-US$166m

Jun 30 2018n/an/a

-US$152m

Mar 31 2018n/an/a

-US$135m

Dec 31 2017US$8mUS$520k

-US$117m

Sep 30 2017n/an/a

-US$103m

Jun 30 2017n/an/a

-US$95m

Mar 31 2017n/an/a

-US$89m

Dec 31 2016US$1mUS$479k

-US$82m

Sep 30 2016n/an/a

-US$71m

Jun 30 2016n/an/a

-US$65m

Mar 31 2016n/an/a

-US$58m

Dec 31 2015US$2mUS$438k

-US$51m

Compensation vs Market: Ted's total compensation ($USD8.19M) is about average for companies of similar size in the US market ($USD6.59M).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.

CEO

Ted Love (63 yo)

8.3yrs

Tenure

US$8,193,309

Compensation

Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...

Leadership Team

NamePositionTenureCompensationOwnership
Ted Love
President8.3yrsUS$8.19m1.37%
$ 63.2m
Jeffrey Farrow
CFO & Principal Accounting Officer6.5yrsUS$2.76m0.040%
$ 1.8m
Jung Choi
Chief Business & Strategy Officer7.5yrsUS$2.73m0.37%
$ 17.2m
David Johnson
Chief Commercial Officer4.6yrsUS$2.75m0.084%
$ 3.9m
Kim Smith-Whitley
Executive VP and Head of Research & Development1.4yrsUS$2.98m0.0089%
$ 409.5k
David Phillips
Founder & Advisor11.8yrsno datano data
Matthew Jacobson
Founder & Advisor11.8yrsno datano data
Andrej Sali
Founder & Advisor11.8yrsno datano data
Nazila Habibizad
Executive Vice President of Operations2.5yrsno data0.062%
$ 2.9m
Stephanie Yao
Senior Director of Corporate Communications & Investor Relationsno datano datano data
Patricia Suvari
Chief Legal Officer & Secretary6yrsUS$5.93m0.064%
$ 3.0m
Steven Immergut
Senior VP & Head of Corporate Communications3.8yrsno datano data

6.5yrs

Average Tenure

60yo

Average Age

Experienced Management: GBT's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ted Love
President9.1yrsUS$8.19m1.37%
$ 63.2m
Mark Perry
Lead Independent Director7.5yrsUS$348.28k0.056%
$ 2.6m
Wendy Yarno
Independent Director4.8yrsUS$320.78k0.017%
$ 783.3k
Deval Patrick
Independent Director2.4yrsUS$313.28k0.013%
$ 618.8k
Glenn Pierce
Independent Director6.7yrsUS$318.28k0.039%
$ 1.8m
Philip Pizzo
Independent Director7.1yrsUS$310.78k0.013%
$ 623.9k
Scott W. Morrison
Independent Director6.8yrsUS$333.28k0.0098%
$ 454.8k
Dawn Svoronos
Independent Director3.8yrsUS$316.36k0.0080%
$ 368.3k
Willie Brown
Advisor & Director Emeritusless than a yearUS$308.28k0.058%
$ 2.7m
Alexis Thompson
Independent Director1.6yrsUS$735.61k0.0049%
$ 226.5k

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: GBT's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/10/05 14:51
End of Day Share Price 2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Global Blood Therapeutics, Inc. is covered by 25 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
John NewmanCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.